Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease is a critical public health challenge in Nigeria, mirroring global concerns. It is a rapidly increasing health issue in both developed and developing countries. The interaction between the genetic and environmental factors may play a role in the development of end-stage renal disease. The HLA allele caries genetic information regarding the transmission of many pathologies, including that of the kidney, and as suggested in some studies, HLA alleles are now attributed to the possibility of developing ESRD, while some may be protective. There is no large-scale study that has mapped HLA alleles distributions in CKD patients or investigated their possible association with CKD. Therefore, this study aims to investigate the distribution of HLA alleles among CKD patients and their potential association with CKD in a Nigerian population.
This is a retrospective cross-sectional study that was carried out at a private health facility in Abuja, Nigeria. HLA data on CKD patients who were on work-up for kidney transplant were retrieved from the laboratory, while HLA data from the pool of prospective non-related donors were also retrieved for the analysis. The HLA typing from DNA samples extracted was performed by Polymerase Chain Reaction - Sequence-Specific Oligonucleotide Probing method. The HLA data was analysed using SPSS version 26 and p-value < 0.005 was considered statistically significant.
The HLA results of a total of 846 recipients and 1017 donors were analyzed in this study. The distribution of HLA – A, HLA – B, and HLA – DR alleles are as shown in figures 1, 2 and 3. Among the samples studied, we identified 108 different alleles. It was observed that the HLA-B alleles were the most polymorphic (52 alleles) as compared to HLA-A (27 alleles), and DR (20 alleles). We used the logistic regression model to adjust for each allele's effect, considering the presence (or absence) of other alleles and to control for potential confounding factors caused by multiple HLA alleles. The following alleles had a statistically significant protective effect for the presence of CKD: HLA-A*23 (OR=0.78 [0.63 – 0.96]), HLA-A*29 (OR=0.47 [0.26 – 0.85]), HLA-B*49 (OR=0.58 [0.37 – 0.89]) and HLA-DR*15 (OR=0.79 [0.65 – 0.96]). On the other hand, alleles HLA-B*42 (OR=1.49 [1.20 – 2.03]), HLA-B*57 (OR=1.38 [1.02 – 1.86]), HLA-B*72 (OR=1.44 [1.04 – 2.00]), and HLA-DR*18 (OR=2.57 [1.70 – 3.89]) were found to have a statistically significant risk effect.
Figure 1: Figure 1: Graphical representation of human leukocyte antigen-A alleles frequencies.
Figure 2: Graphical representation of human leukocyte antigen-B alleles frequencies.
Figure 3: Graphical representation of human leukocyte antigen-DR alleles frequencies
The study's results contribute to a better understanding of HLA allele variability and its influence on CKD susceptibility, which may have implications for donor-recipient matching and improving transplant outcomes. Additionally, this study serves as a background study for the design and conduct of larger studies to find other genetic predisposition to the development of CKD in Nigerians.
